Fiche publication


Date publication

décembre 2014

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme


Tous les auteurs :
Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J,

Résumé

The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III trial.

Mots clés

Aged, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cetuximab, Colonic Neoplasms, drug therapy, Exons, Female, Fluorouracil, Genes, ras, Humans, Leucovorin, Male, Middle Aged, Mutation, Organoplatinum Compounds, Prognosis, Proto-Oncogene Proteins B-raf, genetics

Référence

Ann. Oncol.. 2014 Dec;25(12):2378-85